Vinblastine

Generic Name
Vinblastine
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C46H58N4O9
CAS Number
865-21-4
Unique Ingredient Identifier
5V9KLZ54CY
Background

Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)

Indication

For treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas, mycosis fungoides, histiocytosis, and Kaposi's sarcoma.

Associated Conditions
Advanced Soft Tissue Sarcoma, Autoimmune Hemolytic Anemia, Bladder Cancer, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Letterer-Siwe disease, Metastatic Melanoma, Non-Small Cell Lung Cancer (NSCLC), Advanced Alibert-Bazin syndrome, Advanced Testicular cancer, Histiocytic lymphoma, Refractory Breast cancer
Associated Therapies
-
Clinical Trials
Related News

First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)

First Posted Date
2020-11-20
Last Posted Date
2022-11-01
Lead Sponsor
State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia
Target Recruit Count
300
Registration Number
NCT04638790
Locations
🇮🇳

Tata Memorial Hospital, Mumbai, OPD-81 Main building, Dr. E Borges Road, Parel 400012, India

🇷🇺

The Federal Budget-Funded Institution National Medical Surgical Center named after N. I. Pirogov of the Ministry of health of the Russian Federation, Moscow, Russian Federation

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

First Posted Date
2019-04-11
Last Posted Date
2023-09-11
Lead Sponsor
Stanford University
Target Recruit Count
7
Registration Number
NCT03912818
Locations
🇺🇸

Stanford Cancer Institute Palo Alto, Palo Alto, California, United States

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

First Posted Date
2018-11-28
Last Posted Date
2024-04-04
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
250
Registration Number
NCT03755804
Locations
🇺🇸

Maine Children's Cancer Program, Scarborough, Maine, United States

🇺🇸

St. Jude Affiliate Baton Rouge Clinic (Our Lady of the Lakes Regional Medical Center), Baton Rouge, Louisiana, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

and more 5 locations

Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma

First Posted Date
2018-10-19
Last Posted Date
2024-11-06
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
155
Registration Number
NCT03712202
Locations
🇺🇸

University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

🇺🇸

Hackensack University Medical Center, Hackensack, New Jersey, United States

🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

and more 14 locations

Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

First Posted Date
2018-08-24
Last Posted Date
2024-11-05
Lead Sponsor
Seagen Inc.
Target Recruit Count
255
Registration Number
NCT03646123
Locations
🇺🇸

Texas Oncology - Flower Mound, Flower Mound, Texas, United States

🇺🇸

Clinical Research Alliance - Abraham Mittelman, MD, LLC, Purchase, New York, United States

🇨🇿

Fakultni Nemocnice Kralovske Vinohrady, Praha 10, Other, Czechia

and more 73 locations

Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors

First Posted Date
2018-07-13
Last Posted Date
2024-05-06
Lead Sponsor
Centre Oscar Lambret
Target Recruit Count
63
Registration Number
NCT03585465
Locations
🇧🇪

University Hospital Ghent, Gent, Belgium

🇧🇪

University Hospital Leuven, Leuven, Belgium

🇫🇷

Centre Oscar Lambret, Lille, France

and more 8 locations

Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma

First Posted Date
2018-07-09
Last Posted Date
2022-08-19
Lead Sponsor
The Lymphoma Academic Research Organisation
Target Recruit Count
64
Registration Number
NCT03580408
Locations
🇫🇷

CHU de Clermont Ferrand, Clermont Ferrand, France

🇫🇷

CHU de Dijon - Hôpital le Bocage, Dijon, France

🇧🇪

Clinique Universitaire Saint LUC, Brussels, Belgium

and more 48 locations

OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy

First Posted Date
2018-05-17
Last Posted Date
2019-11-18
Lead Sponsor
King Abdullah International Medical Research Center
Target Recruit Count
220
Registration Number
NCT03527628
Locations
🇸🇦

King Abdulaziz Medical City, Ministry of National Guard, Riyadh, Saudi Arabia

Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study

First Posted Date
2018-05-07
Last Posted Date
2023-11-09
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
150
Registration Number
NCT03517137
Locations
🇳🇱

Amsterdam UMC - Locatie AMC, Amsterdam, Netherlands

🇳🇱

Erasmus MC, Rotterdam, Netherlands

🇵🇱

Maria Sklodowska Curie National Institute of Oncology - National Research Institute, Warsaw, Poland

and more 13 locations

Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)

First Posted Date
2018-01-23
Last Posted Date
2024-11-20
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
340
Registration Number
NCT03407144
Locations
🇺🇸

University of Chicago ( Site 0066), Chicago, Illinois, United States

🇺🇸

Cohen Children's Medical Center of New York ( Site 0052), New Hyde Park, New York, United States

🇺🇸

Columbia University/Herbert Irving Cancer Center ( Site 0063), New York, New York, United States

and more 90 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy